Page 4 - ரால்ஃப் பென்னர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ரால்ஃப் பென்னர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ரால்ஃப் பென்னர் Today - Breaking & Trending Today

Investegate |PAION AG Announcements | PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS

PAION AG
ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
DGAP-News: PAION AG
/ Key word(s): Product Launch
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
28.01.2021 / 07:06
The issuer is solely responsible for the content of this announcement.
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
- Approximately 40 million procedures take place annually in the U.S. that require the use of procedural sedation ....

South Korea , Mike Bolinder , Yichang Humanwell , Hana Pharm , Ralf Penner , Mckesson Medsurg , Jim Phillips , Us Drug Enforcement Administration , Specialty Pharma Company , Drug Administration , Frankfurt Stock Exchange Prime Standard , Cardinal Health , European Medicines Agency , Acacia Pharma , Enforcement Administration , Chief Executive Officer , Marketing Authorization Application , Southeast Asia , United Kingdom , Investegate Announcements , Investegate Company Announcements , Paion Ag , Eqs And , தெற்கு கொரியா , ஹனா பார்ம் , ரால்ஃப் பென்னர் ,

PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS

DGAP-News: PAION AG
/ Key word(s): Product Launch
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
28.01.2021 / 07:06
The issuer is solely responsible for the content of this announcement.
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
- Approximately 40 million procedures take place annually in the U.S. that require the use of procedural sedation
- BYFAVO(TM) is the second Acacia Pharma product approved and launched in the U.S. in the last year and extends its portfolio of new products targeting unmet needs in anesthesia ....

South Korea , Mike Bolinder , Yichang Humanwell , Hana Pharm , Ralf Penner , Mckesson Medsurg , Jim Phillips , Us Drug Enforcement Administration , Specialty Pharma Company , Drug Administration , Frankfurt Stock Exchange Prime Standard , Cardinal Health , European Medicines Agency , Acacia Pharma , Enforcement Administration , Chief Executive Officer , Marketing Authorization Application , Southeast Asia , United Kingdom , Paion Ag Stock Exchange , Press Release , Medi Cal , Minutes Pa8 De000a0b65s3 , தெற்கு கொரியா , ஹனா பார்ம் , ரால்ஃப் பென்னர் ,

Investegate |PAION AG Announcements | PAION AG: PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE

PAION AG
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
DGAP-News: PAION AG
/ Key word(s): Agreement
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
12.01.2021 / 13:42
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH
LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
- PAION in-licenses exclusive rights to commercialize GIAPREZA(TM) and XERAVA(TM) throughout Europe
- La Jolla Pharmaceutical Company to receive USD 22.5 million upfront payment, up to USD 109.5 million in commercial milestone payments, and double-digit tiered royalty payments ....

United Kingdom , South Korea , Larry Edwards , Deutschland Gmb , Ralf Penner , Jim Phillips , Specialty Pharma Company , Pinsent Masons , European Commission , Drug Administration , Frankfurt Stock Exchange Prime Standard , Jolla Pharmaceutical Company , Jolla Pharma , Committee For Medicinal Products Human , European Medicines Agency , Tetraphase Pharmaceuticals Inc , European Investment Bank , European Economic Area , Chief Executive Officer , Market Approval Application , Medicinal Products , Human Use , Destum Partners , Management Board , European Summary , Product Characteristics ,

PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM (BYFAVO) IN GENERAL ANESTHESIA IN SOUT

W
ith the next marketing approval the year 2021 gets off to a promising start for PAION, and we congratulate Hana Pharm on this achievement, said Dr. Jim Phillips, CEO of PAION AG.
With the recently started construction of their own production plant for BYFAVO
TM, our partner continues to invest in the success of BYFAVO
TM and we are looking forward to the upcoming market launch.
Dr. Younha Lee, CEO of Hana Pharm, announced:
We are thrilled to announce BYFAVO
TM approval in South Korea and sincerely thankful for the rewarding partnership with PAION since 2013. Today s approval allows us to leverage Hana Pharm s significant development and commercialization expertise in anesthesiology in South Korea. We will be accelerating the remaining process towards product launch in South Korea and also the regulatory and commercial partnering progress in Singapore, Thailand, Vietnam, Indonesia, the Philippines and Malaysia this year. ....

Republic Of , South Korea , South Korean , Yichang Humanwell , Hana Pharm , Ralf Penner , Younha Lee , Jim Phillips , Korea Ministry Of Food , Specialty Pharma Company , European Medicines Agency , Frankfurt Stock Exchange Prime Standard , Distribution Services , Drug Safety , New Drug Application , Marketing Authorization Application , Acacia Pharma , Southeast Asia , United Kingdom , Regulatory Announcements , Corporate News , குடியரசு ஆஃப் , தெற்கு கொரியா , தெற்கு கொரியன் , ஹனா பார்ம் , ரால்ஃப் பென்னர் ,

Investegate |PAION AG Announcements | PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM (BYFAVO) IN GENERAL ANESTHESIA IN SOUTH KOREA

DGAP-Ad-hoc: PAION AG / Key word(s): Regulatory Approval
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM (BYFAVO) IN GENERAL ANESTHESIA IN SOUTH KOREA
07-Jan-2021 / 11:14 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM (BYFAVO
TM) IN GENERAL ANESTHESIA IN SOUTH KOREA
Aachen (Germany), 07 January 2021 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) announces that Hana Pharm, remimazolam licensee for South Korea, today informed PAION that South Korea s Ministry of Food and Drug Safety (MFDS) has approved the New Drug Application (NDA) for BYFAVO ....

Republic Of , South Korea , South Korean , Yichang Humanwell , Hana Pharm , Ralf Penner , Younha Lee , Jim Phillips , Korea Ministry Of Food , Specialty Pharma Company , European Medicines Agency , Frankfurt Stock Exchange Prime Standard , Distribution Services , Drug Safety , New Drug Application , Marketing Authorization Application , Acacia Pharma , Southeast Asia , United Kingdom , Regulatory Announcements , Corporate News , Investegate Announcements , Investegate Company Announcements , Paion Ag , Eqs And , குடியரசு ஆஃப் ,